All news

Keros Therapeutics board approves $5M share buyback

Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash

Keros Therapeutics' board approved a $5 million share repurchase program for its common stock. The move follows a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., triggered by first patient dosing in the ELRiSE MF clinical trial. Management can buy shares in the open market, with timing and amount subject to market conditions and contractual limits.

Read original source

KROS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.